Recently, InnoCare Medical announced the latest progress and ambitious commercialization goals of its QuanZhen AI medical large model at a highly anticipated performance briefing.
According to information revealed at InnoCare Medical's April 23rd performance briefing, its core product—the QuanZhen AI medical large model—is showing strong growth momentum in commercialization. Data shows that the model achieved a revenue of 4.4 million yuan in 2024 (excluding revenue from primary-level HIS services).
Even more noteworthy is InnoCare Medical's future plan. Company executives stated that in 2024, approximately 60 hospitals collaborated with the QuanZhen AI medical large model. Entering 2025, the company expects to add approximately 100 more collaborating hospitals, further expanding its coverage within medical institutions.
Image Source Note: Image generated by AI, image licensing provider Midjourney
With the rapid expansion of its cooperation network, InnoCare Medical has high hopes for revenue growth from the QuanZhen AI medical large model. The company explicitly stated its goal of achieving 40 million yuan in revenue for the model in 2025. This target, compared to the 4.4 million yuan in 2024, represents a nearly tenfold increase, highlighting the company's strong confidence in the commercial prospects of this AI product.
This series of data and plans clearly shows that InnoCare Medical is accelerating the market promotion and commercial application of its AI medical large model, striving to secure a favorable position in the increasingly competitive AI medical field. Whether the QuanZhen AI medical large model can successfully achieve its ambitious revenue target in the coming year remains to be seen.
